Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokers have set a 1 year consensus price target of $7.00 for the company and are expecting that the company will post ($0.30) EPS for the current quarter, according to Zacks. Zacks has also assigned Kitov Pharmaceuticals Holdings an industry rank of 76 out of 265 based on the ratings given to its competitors.
A number of analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Kitov Pharmaceuticals Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, September 13th. Rodman & Renshaw reaffirmed a “buy” rating on shares of Kitov Pharmaceuticals Holdings in a research report on Monday, July 11th.
Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) opened at 3.48 on Wednesday. The stock has a 50 day moving average of $3.16 and a 200 day moving average of $4.07. The stock’s market capitalization is $23.65 million. Kitov Pharmaceuticals Holdings has a 52 week low of $2.20 and a 52 week high of $6.95.
An institutional investor recently bought a new position in Kitov Pharmaceuticals Holdings stock. Sabby Management LLC acquired a new stake in shares of Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 232,524 shares of the company’s stock, valued at approximately $725,000. Sabby Management LLC owned about 5.96% of Kitov Pharmaceuticals Holdings as of its most recent SEC filing.
Kitov Pharmaceuticals Holdings Company Profile
Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kitov Pharmaceuticals Holdings Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals Holdings Ltd and related companies with MarketBeat.com's FREE daily email newsletter.